

# **Sterile Compounding Inspections**

**Gay Dodson, R.Ph**

**Executive Director/Secretary**

**Texas State Board of Pharmacy**

**FDA's 2016 Inter-governmental Working  
Meeting on Pharmacy Compounding**

**September 21, 2016**



**TEXAS STATE BOARD OF PHARMACY**

# Board of Pharmacy Members

---

**Jeanne D. Waggener, R.Ph.**

President – Waco

**Christopher M. Dembny, R.Ph.**

Vice President – Richardson

**Alice G. Mendoza, R.Ph.**

Treasurer – Kingsville

**Buford T. Abeltd, Sr., R.Ph.**

Lufkin

**L. Suzan Kedron**

Dallas

**Bradley A. Miller, Ph.T.R.**

Austin

**Phyllis A. Stine**

Abilene

**Chip Thornsburg**

San Antonio

**Suzette Tijerina, R.Ph.**

Castle Hills

**Dennis F. Wiesner, R.Ph.**

Austin

**Jenny Downing Yoakum, R.Ph.**

Kilgore





# Licensing of Pharmacies

---

- The Texas State Board of Pharmacy licenses all pharmacies located in:
  - Texas (Community, Hospital, etc.); and
  - Other states, if the pharmacies dispense and ship prescription drugs to Texas residents.



# Texas Pharmacy Act

---

• The Texas Pharmacy Act specifies that:

- New sterile compounding pharmacies may not open until inspected; and
- Existing sterile compounding pharmacies may NOT renew their Biennial registration unless they have:
  - Been inspected as specified by the Board rules; and
  - If located in a state other than Texas, reimbursed the Board for all expenses incurred by the Board in inspecting the pharmacy.



# Texas Pharmacy Act (cont.)

---

- The Texas Pharmacy Act requires:
  - A pharmacy that compounds a sterile product to notify the Board:
    - Immediately of any adverse effects reported to the pharmacy or known by the pharmacy to be potentially attributable to a sterile product compounded by the pharmacy; and
    - Not later than 24-hours after the pharmacy issues a recall for a sterile product compounded by the pharmacy.



# Training of Pharmacists that Compound Sterile Pharmaceuticals

---

- All pharmacists who compound sterile preparations or supervise pharmacy technicians compounding sterile preparations must complete through a single course, a minimum of 20 hours of instruction and experience in the areas listed in the rules.



# Pharmacists' Training

---

- The pharmacists' training must be obtained through completion of a:
  - Recognized course in an accredited college of pharmacy; or
  - Course sponsored by an ACPE accredited provider covering the items listed in Board rules.





# Training of Pharmacy Technicians that Compound Sterile Pharmaceuticals

---

- Pharmacy technicians must have completed a 40-hour course provided by an ACPE approved provider covering the items listed in Board rules.



# Inspections of Sterile Compounding Pharmacies (FY2015)

---

## # OF PHARMACIES THAT COMPOUND STERILE PRODUCTS

	Class A-S	Class C-S	Class E-S	Totals
	144	128	66	338

Note: Pharmacies located within Texas are inspected by TSBP staff.

Pharmacies located in a state other than Texas are inspected by TSBP staff or by inspectors contracted and trained by TSBP.



# FY2015 Inspection Violations

<b>Inspection Violations (Warning Notices Issued)</b>	
<b>Unsanitary</b>	<b>32</b>
<b>Improper Environment</b>	<b>137</b>
<b>Incomplete QA/QC</b>	<b>99</b>
<b>No/Incomplete P&amp;P Manual</b>	<b>237</b>
<b>No/Inadequate Preparation Area</b>	<b>165</b>
<b>Cytotoxic/Bio Procedures</b>	<b>2</b>



# Problem Inspections

---

- If an inspector finds problems that he/she considers a danger to the public, the pharmacy is given the opportunity to voluntary cease the problem activity.
- If the pharmacy refuses to cease the activity, a temporary suspension hearing to immediately suspend the license of the pharmacy will be scheduled.



# Testing of Compounded Products

## SUMMARY OF COMPOUNDED SAMPLE TESTING PROGRAM FY 2011 – FY 2015

	FY2011	FY2012	FY2013	FY2014	FY2015	5-Yr. Avg.
<b>Total # Samples Tested</b>	<b>37</b>	<b>28</b>	<b>58</b>	<b>124</b>	<b>193</b>	<b>88</b>
<b># Non-Sterile Samples Tested</b>	<b>27</b>	<b>20</b>	<b>9</b>	<b>7</b>	<b>24</b>	<b>17</b>
<b># Potency Failures</b>	<b>4</b>	<b>2</b>	<b>1</b>	<b>2</b>	<b>5</b>	<b>3</b>
<b># Sterile Samples Tested</b>	<b>10</b>	<b>8</b>	<b>49</b>	<b>117</b>	<b>169</b>	<b>71</b>
<b># Potency Failures</b>	<b>4</b>	<b>1</b>	<b>2</b>	<b>9</b>	<b>24</b>	<b>0</b>
<b># Sterility Failures</b>	<b>0</b>	<b>1**</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>&lt;1</b>
<b># Fungal Failures*</b>	<b>N/A</b>	<b>N/A</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b># Endotoxin Failures</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

\*Fungal Testing began in FY2012

\*\*Nasal product